 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Olaparib maintenance treatment for advanced ovarian cancer followed up to 7 years of overall survival prognosis

J Clin Oncol: Olaparib maintenance treatment for advanced ovarian cancer followed up to 7 years of overall survival prognosis

 Last Update: 2022-10-02
 Source: Internet
 Author: User

Tags

sodium benzoate cancer

5 10 models

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In the SOLO1/GOG 3004 trial, maintenance therapy with the poly (ADP-ribose) polymerase inhibitor olaparib provides a sustained progression-free survival benefit

In this double-blind, phase 3 clinical trial, newly diagnosed patients with advanced ovarian cancer who responded to platinum-based chemotherapy with BRCA mutations were randomly assigned to the olaparib group (n=260) or placebo group (n=131) for maintenance for up to 2 years

As of July 2022, 149 of the 391 patients have died

At year 7, 67.

Taken together, the findings suggest that in newly diagnosed patients with advanced ovarian cancer with BRCA mutations, olaparib maintenance therapy improves overall survival prognosis and has clinical significance, although there is no statistical significance according to predetermined criteria; Support these patients with olaparib maintenance therapy for long-term remission

Original Source:

Paul DiSilvestro, et al.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.